[CAS NO. 117570-53-3] Vadimezan (ASA404)

Name: Vadimezan (ASA404)
Brand: Arctom Scientific
SKU: SLK-S1537

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [117570-53-3]

Store

Catalog

SLK-S1537

Brand

Selleck

CAS

117570-53-3

DESCRIPTION [117570-53-3]

Overview

MDL	MFCD00870555
Molecular Weight	282.29
Molecular Formula	C17H14O4
SMILES	C(C(O)=O)C1=C2C(C(=O)C=3C(O2)=C(C)C(C)=CC3)=CC=C1

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	3.5425 mL	17.7123 mL	35.4246 mL
5 mM	0.7085 mL	3.5425 mL	7.0849 mL
10 mM	0.3542 mL	1.7712 mL	3.5425 mL
50 mM	-	-	-

Description

Vadimezan (ASA404, NSC 640488, DMXAA) is a and competitive inhibitor of with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a agonist with potential antineoplastic activity. DMXAA (Vadimezan) potently induces but relatively low expression in vitro. DMXAA (Vadimezan) has antiviral activity. Phase 3.

Targets

DT-diaphorase ^[1] (Cell-free assay)	DT-diaphorase ^[1] (Cell-free assay)
20 μM(Ki)	20 μM(Ki)

In vitro

In DLD-1 human colon carcinoma cells, DMXAA inhibits DT-diaphorase activity without significant effects on the activity of cytochrome b5 reductase and cytochrome P450 reductase. Combination of menadione and DMXAA leads to an increase in the antiproliferative activity of DLD-1 cells. DMXAA, as an antiviral agent, inhibits VSV-induced cytotoxicity and influenza virus replication in RAW 264.7 macrophages. A recent study shows that DMXAA has non-immune-mediated inhibitory effects against several kinase members of VEGFR (vascular endothelial growth factor receptor), such as VEGFR2 signalling in human umbilical vein endothelial cells.

In vivo

DMXAA treatment significantly protects C57BL/6J mice infected i.n. with 200 p.f.u. mouse-adapted H1N1 influenza PR8 virus with 60% survival, while the control group only exhibited 20% survival. DMXAA significantly delays tumor growth induced by chemical carcinogen, increases the time to tumor doubling and increases time from treatment to euthanasia. After the treatment of DMXAA, median tumor doubling time, median tumour tripling time and median time from treatment to euthanasia in tumor-bearing animals are increased by approximately 4.4-, 1.8- and 2.7-fold, respectively.

References

[1] Phillips RM. Biochem Pharmacol. 1999, 58(2), 303-310.
[2] Shirey KA, et al. J Leukoc Biol. 2011, 89(3), 351-357.
[3] Buchanan CM, et al. Clin Sci (Lond). 2012, 122(10), 449-457.
[4] Liu JJ, et al. Cancer Chemother Pharmacol. 2007, 59(5), 661-669.

Synonyms

9H-Xanthene-4-acetic acid, 5,6-dimethyl-9-oxo-

5,6-Dimethyl-9-oxo-9H-xanthene-4-acetic acid

5,6-Dimethylxanthenone-4-acetic acid

NSC 640488

DMXAA

AS 1404

5,6-Dimethyl-9-oxo-9H-xanthen-4-ylacetic acid

Vadimezan

ASA 404

2-(5,6-Dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid

D5817

2-(5,6-Dimethyl-9-oxoxanthen-4-yl)acetic acid